Recent Updates
Recently added Catalysts
COR Positive Sentiment Score: 85/100

CENCORA ANNOUNCES COMMON SHARE REPURCHASE FROM WALGREENS BOOTS ALLIANCE AND RAISES FISCAL 2024

Key Takeaway: Cencora, Inc. announced a share repurchase agreement with Walgreens Boots Alliance totaling approximately $400 million. This decision is part of an opportunistic strategy to manage shares more effectively. Additionally, the company has raised its fiscal year 2024 adjusted diluted earnings per share guidance from $13.30-$13.50 to $13.35-$13.55, reflecting a favorable financial outlook. The repurchase is expected to lower the weighted average diluted share count despite increased interest expenses due to reduced investment balances.

Market Sentiment Analysis

POSITIVE FACTORS

  • Cencora is repurchasing $400 million in shares, boosting investor confidence.
  • The company raised its fiscal 2024 earnings per share guidance, indicating strong financial performance.
  • Cencora has completed approximately $550 million in share repurchases in May alone.

Full Press Release Details

CENCORA ANNOUNCES COMMON SHARE REPURCHASE FROM WALGREENS BOOTS ALLIANCE AND RAISES FISCAL 2024 GUIDANCE
CONSHOHOCKEN, PA, May 22, 2024 - Cencora, Inc. (NYSE: COR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $400 million in a private transaction.
Cencora is also raising its fiscal year 2024 adjusted diluted earnings per share guidance to $13.35 to $13.55, up from the previous range of $13.30 to $13.50, to reflect a lower weighted average diluted share count, partially offset by higher net interest expense due to lower investment balances as a result of cash being used for share repurchases. This transaction is an example of the Company's opportunistic approach to share repurchases and the Company will now have completed approximately $550 million of share repurchases in the month of May.
Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Our 46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more than $250 billion in annual revenue.
Cencora's Cautionary Note Regarding Forward-Looking Statements
Certain of the statements contained in this press release, including, without limitation, those regarding the Company's updated adjusted diluted earnings per share guidance, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Securities Exchange Act"). Words such as "aim," "anticipate," "believe," "can," "continue," "could,", "estimate," "expect," "intend," "may," "might," "on track," "opportunity," "plan," "possible," "potential," "predict," "project," "seek," "should," "strive," "sustain," "synergy," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. These statements are not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially from those indicated is included in the "Risk Factors" and "Management's Discussion and Analysis" sections in the Company's Annual Report on Form 10-K for the fiscal year ended September, 30, 2023 and elsewhere in that report and (ii) other reports filed by the Company pursuant to the Securities Exchange Act. The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.
Contacts: Bennett S. Murphy
Senior Vice President, Head of Investor Relations & Treasury
610-727-3693
Bennett.Murphy@cencora.com

Frequently Asked Questions

What share repurchase agreement did Cencora announce?

Cencora announced a $400 million share repurchase from Walgreens Boots Alliance.

What is Cencora's adjusted earnings guidance for fiscal 2024?

Cencora raised its fiscal 2024 guidance to $13.35 to $13.55 per share.

How much has Cencora repurchased in May 2024?

Cencora has completed approximately $550 million in share repurchases in May.

What role does Cencora play in the pharmaceutical sector?

Cencora partners with innovators to enhance market access to pharmaceutical therapies.

Where does Cencora rank in the Fortune 500?

Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500.

Last updated: May 22, 2024